VivoSeq
Other

STEMI

0

Pipeline Programs↗

9

Active Trials↗

1

Companies Involved↗

STEMI is an early-stage landscape with 0 programs across 1 company. The most active players are Faraday Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Faraday Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

35

clinical trials

Completed13 · 37%
Unknown status12 · 34%
Recruiting7 · 20%
Not yet recruiting1 · 3%
Active, not recruiting1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

35 trials

Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
Recruiting·—·Phase 4·NCT04347434·300 enrolled
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Recruiting·KKafrelsheikh University·N/A·NCT06966674·60 enrolled
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Recruiting·MMinneapolis Heart Institute Foundation·Phase 2·NCT05305911·81 enrolled
Cohort of STEMI Patients 2
Recruiting·HHospices Civils de Lyon·N/A·NCT05794022·300 enrolled
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
Recruiting·HHenan Institute of Cardiovascular Epidemiology·Phase 4·NCT06769256·300 enrolled
Early Beta Blocker Administration in STEMI Patients With SCAI B Status
Recruiting·TTel-Aviv Sourasky Medical Center·N/A·NCT06967194·200 enrolled
Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial
Recruiting·—·N/A·NCT07361783·6,294 enrolled
Evolocumab in STEMI
Active, not recruiting·SSejong General Hospital·Phase 3·NCT06081803·166 enrolled
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
Not yet recruiting·JJena University Hospital·N/A·NCT05587621·300 enrolled
CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI
Completed·MMaasstad Hospital·Phase 4·NCT03296540·729 enrolled
Pharmacological Effects of Crushing Prasugrel in STEMI Patients
Completed·UUniversity of Florida·Phase 4·NCT02212028·52 enrolled
Early Administration of Heparin At FMC for PPCI of STEMI Patients
Completed·RRenmin Hospital of Wuhan University·N/A·NCT05329155·1,145 enrolled
Adjunctive, Low-dose tPA in Primary PCI for STEMI
Completed·PPopulation Health Research Institute·Phase 3·NCT03335839·210 enrolled
Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients
Completed·SSheba Medical Center·Phase 4·NCT02725099·50 enrolled
Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI
Completed·—·Phase 4·NCT02943369·30 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)